This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Breast Cancer
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
-
Research Site, Daphne, Alabama, United States, 36526
Research Site, Springdale, Arkansas, United States, 72762
Research Site, Duarte, California, United States, 91010
Research Site, Glendale, California, United States, 91204
Research Site, Sacramento, California, United States, 95817
Research Site, Santa Rosa, California, United States, 95403
Research Site, Aurora, Colorado, United States, 80012
Research Site, New Haven, Connecticut, United States, 06510
Research Site, Jacksonville, Florida, United States, 32256
Research Site, Miami, Florida, United States, 33176
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
AstraZeneca,
2029-04-23